LMR Partners’s Ionis Pharmaceuticals IONS Stock Holding History

LMR Partners’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.13M	Hold	15,000	–	–	﹤0.01%	959
2025 Q4	$1.19M	Sell	15,000 -22,600	-60%	-$1.7M	﹤0.01%	944
2025 Q3	$2.46M	Buy	+37,600	New	+$1.84M	0.01%	674
2020 Q1	–	Sell	-28,809	Closed	-$1.74K	–	341
2019 Q4	$1.74K	Buy	28,809 +24,781	+615%	+$1.48M	﹤0.01%	145
2019 Q3	$241K	Buy	+4,028	New	+$263K	0.01%	335
2019 Q2	–	Sell	-51,950	Closed	-$4.22M	–	506
2019 Q1	$4.22M	Buy	+51,950	New	+$3.35M	0.22%	69
2016 Q4	–	Sell	-144,790	Closed	-$5.3M	–	364
2016 Q3	$5.3M	Buy	+144,790	New	+$4.53M	0.5%	50

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LMR Partners's IONS Position: Q1 2026 in Review

LMR Partners held its Ionis Pharmaceuticals (IONS) position steady in Q1 2026 at 15,000 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #959.

LMR Partners first reported a position in IONS in Q3 2016 and has held it in 7 quarters since. The position peaked at $5.3M in Q3 2016. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

LMR Partners held 15,000 shares of Ionis Pharmaceuticals worth $1.13M as of Q1 2026.
LMR Partners left its Ionis Pharmaceuticals share count unchanged in Q1 2026.
Ionis Pharmaceuticals made up ﹤0.01% of LMR Partners's portfolio in Q1 2026, its #959 holding.
LMR Partners first reported a position in Ionis Pharmaceuticals in Q3 2016 and has held it in 7 quarters since.
LMR Partners's Ionis Pharmaceuticals position peaked at $5.3M in Q3 2016.
493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.